Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Ancell
CD272 [BTLA] (human)-muIg Fusion Protein
551
CHF
CHF 551.00
In stock
ANC-542-02025 µgCHF 551.00
Product Details | |
---|---|
Synonyms | BTLA; B- and T-lymphocyte Attenuator |
Product Type | Protein |
Properties | |
Source/Host | CHO cells |
Application |
ELISA |
Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate |
Protein Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Declaration | Manufactured by Ancell Corporation. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | +4°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 6 months after receipt when stored at +4°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
Human CD272 (BTLA; B and T Lymphocyte Attenuator) is a member of the immunoglobulin superfamily and has sequence homology to PD-1 and CTLA-4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand CD270 (HVEM) can downregulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines. Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis.